In Section C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until illness progression or even the participants are unable to tolerate the study drugs. - Participant eaten grapefruit or grapefruit products within 3 days before the https://cesarz221nyi4.bleepblogs.com/profile